Q32 Bio Inc. (QTTB)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Q32 Bio Inc. (QTTB) trades at $3.37 with AI Score 46/100 (Weak). Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapeutics for autoimmune and inflammatory diseases. Market cap: 41460466, Sector: Healthcare.
Last analyzed: Feb 9, 2026Q32 Bio Inc. (QTTB) Healthcare & Pipeline Overview
Q32 Bio Inc. pioneers biologic therapeutics for autoimmune and inflammatory diseases, leveraging its innovative ADX-097 and Bempikibart (ADX-914) pipeline to restore immune balance. With a focus on high unmet needs and a market cap of $0.05B, QTTB presents a notable opportunity in the biotechnology sector.
Investment Thesis
Q32 Bio Inc. presents a notable research candidate within the biotechnology sector, driven by its innovative pipeline targeting autoimmune and inflammatory diseases. The company's lead candidate, ADX-097, addresses significant unmet needs in complement-mediated diseases, offering potential for substantial market penetration upon successful clinical development and regulatory approval. The advancement of Bempikibart (ADX-914) in Phase II trials for atopic dermatitis and alopecia areata further diversifies the company's portfolio and expands its potential market reach. With a market capitalization of $0.05B and a beta of 0.17, QTTB offers a potentially undervalued entry point for investors seeking exposure to innovative biotechnology. Key value drivers include positive clinical trial results for ADX-097 and Bempikibart, strategic partnerships, and potential acquisition by larger pharmaceutical companies. The company's focus on biologics and its experienced management team further strengthen the investment thesis.
Based on FMP financials and quantitative analysis
Key Highlights
- Lead product candidate ADX-097 completed Phase I clinical trial, demonstrating potential for treating complement-mediated diseases.
- Bempikibart (ADX-914) is currently in Phase II clinical trials for atopic dermatitis and alopecia areata, expanding the company's therapeutic focus.
- Market capitalization of $0.05B provides a potentially undervalued entry point for investors.
- Beta of 0.17 indicates lower volatility compared to the broader market.
- Focus on biologic therapeutics aligns with the growing trend towards targeted and personalized medicine.
Competitors & Peers
Strengths
- Innovative pipeline of biologic therapeutics.
- Targeting high unmet medical needs in autoimmune and inflammatory diseases.
- Experienced management team.
- Completed Phase I clinical trial for lead product candidate ADX-097.
Weaknesses
- Clinical-stage company with no approved products.
- Limited financial resources.
- High risk of clinical trial failure.
- Reliance on a small number of product candidates.
Catalysts
- Upcoming: Phase II clinical trial results for Bempikibart (ADX-914) in atopic dermatitis (2026-2027).
- Upcoming: Initiation of Phase II clinical trials for Bempikibart (ADX-914) in alopecia areata (2026).
- Ongoing: Continued development of ADX-097 for complement-mediated diseases.
- Ongoing: Potential for strategic partnerships and collaborations.
Risks
- Potential: Clinical trial failures for ADX-097 or Bempikibart (ADX-914).
- Potential: Regulatory delays or rejection of product candidates.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: Limited financial resources and the need for additional funding.
- Potential: Changes in the healthcare landscape and reimbursement policies.
Growth Opportunities
- Expansion of ADX-097 into additional indications: ADX-097, currently targeting renal and complement-mediated diseases, has the potential to be expanded into other autoimmune disorders driven by complement dysregulation. The market for autoimmune disease therapies is estimated to reach $150 billion by 2028. Successful clinical trials in new indications could significantly increase ADX-097's market potential. Timeline: 2027-2030.
- Advancement of Bempikibart (ADX-914) through clinical trials: Positive results from the ongoing Phase II trials for atopic dermatitis and alopecia areata could pave the way for pivotal Phase III trials and eventual regulatory approval. The market for atopic dermatitis and alopecia areata therapies is growing, driven by increasing prevalence and unmet needs. Timeline: 2026-2028.
- Strategic partnerships and collaborations: Q32 Bio can leverage strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships can provide access to funding, expertise, and distribution networks. Timeline: Ongoing.
- Expansion of the pipeline through internal research and development: Q32 Bio can continue to invest in internal research and development to expand its pipeline with novel biologic therapeutics targeting other autoimmune and inflammatory diseases. This will diversify the company's portfolio and reduce its reliance on its lead product candidates. Timeline: Ongoing.
- Potential acquisition by a larger pharmaceutical company: Given its innovative pipeline and focus on high-value therapeutic areas, Q32 Bio is an attractive acquisition target for larger pharmaceutical companies seeking to expand their portfolios. An acquisition could provide significant returns for investors. Timeline: 2027-2030.
Opportunities
- Expansion of ADX-097 into additional indications.
- Advancement of Bempikibart (ADX-914) through clinical trials.
- Strategic partnerships and collaborations.
- Potential acquisition by a larger pharmaceutical company.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Unfavorable clinical trial results.
- Changes in the healthcare landscape.
Competitive Advantages
- Proprietary biologic therapeutics targeting specific immune pathways.
- Strong intellectual property protection for its product candidates.
- Clinical trial data demonstrating the safety and efficacy of its therapies.
- Experienced management team with expertise in drug development and commercialization.
About QTTB
Founded in 2017 and based in Waltham, Massachusetts, Q32 Bio Inc. is a clinical-stage biotechnology company dedicated to developing innovative biologic therapeutics. The company targets autoimmune and inflammatory diseases, focusing on restoring healthy immune balance in patients suffering from pathological immune dysfunction. Q32 Bio's lead product candidate, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to restore complement regulation. ADX-097 has completed Phase I clinical trials and is being developed for the treatment of renal and other complement-mediated diseases with significant unmet needs, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also advancing Bempikibart (ADX-914), a fully human anti-interleukin-7 receptor alpha antagonist monoclonal antibody. Bempikibart aims to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin. Currently, Bempikibart is in Phase II clinical trials for the treatment of atopic dermatitis and alopecia areata. Formerly known as AdMIRx Inc., Q32 Bio Inc. adopted its current name in April 2020, marking a strategic shift towards its current focus on immune-modulating biologics.
What They Do
- Develop biologic therapeutics for autoimmune and inflammatory diseases.
- Focus on restoring healthy immune balance in patients with pathological immune dysfunction.
- Develop ADX-097, a humanized anti-C3d monoclonal antibody fusion protein, for complement-mediated diseases.
- Advance Bempikibart (ADX-914), a fully human anti-interleukin-7 receptor alpha antagonist monoclonal antibody, for atopic dermatitis and alopecia areata.
- Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
- Target diseases with high unmet medical needs.
Business Model
- Develop and commercialize biologic therapeutics for autoimmune and inflammatory diseases.
- Generate revenue through sales of approved products.
- Potentially generate revenue through licensing agreements and strategic partnerships.
- Fund research and development activities through venture capital and potential future public offerings.
Industry Context
Q32 Bio Inc. operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation, high regulatory hurdles, and significant market potential. The autoimmune and inflammatory disease market is substantial, driven by increasing prevalence and unmet medical needs. Q32 Bio's focus on biologic therapeutics positions it favorably within this market, as biologics offer targeted and often more effective treatments compared to traditional small molecule drugs. The company faces competition from established pharmaceutical companies and other biotechnology firms developing therapies for similar indications. Key industry trends include the increasing adoption of precision medicine, the growing importance of biomarkers, and the rising demand for novel therapies with improved efficacy and safety profiles.
Key Customers
- Patients with autoimmune and inflammatory diseases.
- Healthcare providers who prescribe and administer the company's therapies.
- Pharmaceutical companies who may partner with or acquire the company.
Financials
Chart & Info
Q32 Bio Inc. (QTTB) stock price: $3.37 (-0.07, -2.03%)
Latest News
-
Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know
Zacks · Mar 19, 2026
-
Wall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
Zacks · Mar 13, 2026
-
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
benzinga · Feb 25, 2026
-
12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga · Jul 10, 2025
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for QTTB.
Price Targets
Wall Street price target analysis for QTTB.
MoonshotScore
What does this score mean?
The MoonshotScore rates QTTB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know
Wall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
12 Health Care Stocks Moving In Thursday's Intraday Session
Latest Q32 Bio Inc. Analysis
What Investors Ask About Q32 Bio Inc. (QTTB)
What does Q32 Bio Inc. do?
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapeutics for autoimmune and inflammatory diseases. Their primary focus is on restoring healthy immune balance in patients suffering from pathological immune dysfunction. The company's lead product candidate, ADX-097, is designed to treat complement-mediated diseases, while Bempikibart (ADX-914) is being developed for atopic dermatitis and alopecia areata. Q32 Bio aims to address significant unmet medical needs by developing innovative therapies that target specific immune pathways and offer improved efficacy and safety profiles compared to existing treatments.
Is QTTB stock worth researching?
QTTB presents a speculative investment opportunity, typical of clinical-stage biotechnology companies. With a market cap of $0.05B and a negative P/E ratio of -1.23, the company is currently not profitable. The value proposition hinges on the successful development and commercialization of its pipeline, particularly ADX-097 and Bempikibart (ADX-914). Positive clinical trial results and potential partnerships could drive significant stock appreciation. However, investors should be aware of the inherent risks associated with biotechnology investments, including clinical trial failures, regulatory hurdles, and competition. A balanced approach considering the potential upside and downside is crucial before investing in QTTB.
What are the main risks for QTTB?
The main risks for Q32 Bio Inc. are inherent to its stage and industry. Clinical trial risk is paramount; failure of ADX-097 or Bempikibart (ADX-914) in clinical trials would significantly impact the company's value. Regulatory risk is also substantial, as approval of new therapies is subject to stringent review processes. Competition from larger pharmaceutical companies with greater resources poses a continuous threat. Financial risk is also a concern, as Q32 Bio relies on external funding to support its research and development activities. Changes in the healthcare landscape, such as shifts in reimbursement policies, could also negatively affect the company's prospects.
What are the key factors to evaluate for QTTB?
Q32 Bio Inc. (QTTB) currently holds an AI score of 46/100, indicating low score. Key strength: Innovative pipeline of biologic therapeutics.. Primary risk to monitor: Potential: Clinical trial failures for ADX-097 or Bempikibart (ADX-914).. This is not financial advice.
How frequently does QTTB data refresh on this page?
QTTB prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven QTTB's recent stock price performance?
Recent price movement in Q32 Bio Inc. (QTTB) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative pipeline of biologic therapeutics.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider QTTB overvalued or undervalued right now?
Determining whether Q32 Bio Inc. (QTTB) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying QTTB?
Before investing in Q32 Bio Inc. (QTTB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment in biotechnology companies is inherently risky.
- This is not financial advice. Conduct thorough research before making any investment decisions.